UniQure to Seek FDA Approval for Huntington's Disease Gene Therapy
Drugmaker UniQure is set to seek approval from the U.S. Food and Drug Administration (FDA) for its gene therapy designed to treat Huntington's disease. This move occurs months after the company engaged in a public debate with FDA leaders concerning the clinical trial data supporting its application.
UniQure, a pharmaceutical company, plans to seek U.S. Food and Drug Administration (FDA) approval for its gene therapy developed to treat Huntington's disease.
This decision comes several months after the drugmaker was involved in a public disagreement with FDA leaders. The dispute centered on the clinical trial data that supported UniQure's application for the therapy.
According to CNBC Business, this announcement follows previous public discussions between UniQure and FDA leaders regarding clinical trial data.
